- Home
- PARR vs ATAI Comparison
PARR vs ATAI Comparison
Compare PARR & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PARR | ATAI |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2000 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PARR | ATAI |
|---|---|---|
| Price | $83.75 | $7.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $70.17 | $15.88 |
| AVG Volume (30 Days) | 756.4K | ★ 13.5M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | N/A |
| EPS | ★ 10.43 | N/A |
| Revenue | ★ $2,443,066,000.00 | $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $8.02 | ★ N/A |
| Revenue Growth | 30.99 | ★ 1227.60 |
| 52 Week Low | $33.28 | $3.27 |
| 52 Week High | $87.03 | $7.45 |
Technical Indicators
Market Signals| Indicator | PARR | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 62.24 |
| Support Level | $55.45 | $3.32 |
| Resistance Level | $85.37 | N/A |
| Average True Range (ATR) | 4.16 | 0.08 |
| MACD | 0.24 | -0.05 |
| Stochastic Oscillator | 62.54 | 50.23 |
Price Performance
Historical ComparisonAbout PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.